@article{e0c3871fc09243be9025c56216d71ac1,
title = "Phase I trial of desmethylmisonidazole. A new hypoxic cell sensitizer",
author = "Wassermanl, {T. H.} and Coleman, {C. N.} and Phillips, {T. L.} and J. Strong and R. Urtasun and J. Schwade",
note = "Funding Information: T.H. Wasserman', C.N. Coleman2, T.L. Phillips3, J. Strong4, R. Urtasun5, J. Schwade4 lwashington Univ., St. Louis, MO, 2Stanfora Univ., Stanford, CA, 3Univ. of Calif. at San Francisco, San Francisco, CA 4National Cancer Inst., Bethesda, MD, 5Univ. of Alberta, Edmonton, Canada Under the auspices of Radiation Therapy Oncology Group (RTOG) ano the Division of Cancer Treatment, National Cancer Institute (Grant # 3RlOCA122261-09Sl) The hypoxic cell radiosensitizer, Desmethylmisonidazole (DMM), is in Phase I clinical pharmacology and toxicology trial. This compound is an endogenously formeo analog of the previously tested radiosensitizer Misonidazole (Miso). DMM has an advantage over Miso of lower lipophilicity which allows for an IV preparation of DMM, for anticipated improved renal clearance, for lower penetration into neural tissues, but with maintenance of good peak sera levels. The current Phase I study opened January 24, 1981, and has accessioned 22 cases to date. All patients have advanced cancer but normal renal and hepatic function. The drug, DMM, is administered via an IV infusion, on an escalating schedule of number of doses per week and size of",
year = "1981",
doi = "10.1016/0360-3016(81)90548-4",
language = "English (US)",
volume = "7",
pages = "1228--1229",
journal = "Unknown Journal",
issn = "0309-1708",
publisher = "Elsevier Limited",
number = "9",
}